MAR 0 6 2006

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

k Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: March 3, 2006

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known					
Application Number	09/715,764				
Filing Date	11/15/2000				
First Named Inventor	Heinz-Josef LENZ				
Group Art Unit	1634				
Examiner Name	Sitton, Jehanne Souaya				
Attorney Docket Number	064189-0201 (2924)				

	U.S. PATENT DOCUMENTS								
_		U.S. Patent D	ocument	Name of Patentes or Applicant of Cited Document	Date of Publication of	Pages, Columns, Lines, Where Relevant			
Examiner Initials*	Cite No. ¹	Number	Kind Code ² (if known)		Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear			
90	1	5,705,336		Reed, et al.	01-06-1998				
90	2	6,716,581	B2	Lenz et al.	04-06-2004				
Op.	3	2004/0067519	A1	Lenz et al.	04-08-2004				
						•			
•									
	-								

U.S. Patent Application			Pages, Columns, Lines,
Document	Name of Botanton or Applicant of	Filing Date of	Where Relevant
Serial Number Kind Code ² (if known)	Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
_	Serial Number Kind Code ² (if	Serial Number Code ² (if Cited Document	Serial Number Code ² (if Cited Document MM-DD-YYYY

		F(PREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No.1	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
D	4	WO 01/36686	University of Southern California	05-25-2001		

Examiner Signature	Jehans	e Sith	Date Considered	10/6/06
SEVALUNED.	halffal Wanda	A ash a a a a a a a a a a a a a a a a a a		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (MPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

MAR 0 6 2006 Under the Papery

Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO Complete if Known PADEN INFORMATION DISCLOSURE **Application Number** 09/715,764 STATEMENT BY APPLICANT 11/15/2000 Filing Date First Named Inventor Heinz-Josef LENZ Date Submitted: March 3, 2006 **Group Art Unit** 1634 (use as many sheets as necessary) **Examiner Name** Sitton, Jehanne Souaya Sheet 2 of 3 **Attorney Docket Number** 064189-0201 (2924)

	FOREIGN PATENT DOCUMENTS										
Examiner Initials*	Cite No. ¹	Foreign Patent Document Office ³ Number ⁴ Kind Co	ode	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶				
	5	WO 01/75175		University of Southern California	10-11-2001						
	6	WO 2004/011625		University of Southern California	02-05-2004						
	7	WO 2004/037852	A2	University of Medicine and Dentistry of New Jersey	05/04/2004						
	8	WO 2004/037852	A3	University of Medicine and	05/04/2004						
				Dentistry of New Jersey			+				

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
.90	9	ELDER et al. "Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer." Clinical Cancer Res. April 2000, Vol. 6, pages 1378-1384.	
. [10	Fox et al. "Angiogenesis in normal tissue adjacent to colon cancer" <i>Journal of Surgical Oncology</i> (Dec. 1998) 69(4):230-234	
	11 .	IACOPETTA et al. "A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil" Brit. J. Cancer Sept. 2001, Vol. 85, No. 6, pages 827-830.	
	12	ISHIKAWA et al. *Dihydropyrimidien dehydorgenase activity and messenger RNA level may be related to the antitumor effect of 5-flurouracil on human tumor xenografts in nude mice* Clin. Cancer Res., April 1999, Vol. 5, pages 883-889.	
	13	Kuniyasu et al. "Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer" American Journal of Pathology (Nov. 2000) 1575):1523-1535	
	14	LENZ et al. "A 6 base-pair deletion in the 3' UTR of the thymidylate synthase (TS) gene predicts TS mRNA expression in colorectal tumors: a possible candidate gene for colorectal cancer risk" PNAS, March 2002, Vol. 43, page 660 (abstract only).	
T	15	Liotta et al. "The microenvironment of the tumour-host interface" Nature (May 2001) 411(6835):375-379	

Examiner Signature	Ichanne	SHA	Date Considered	10/6/96

MINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (MPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Par ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

CONDE	Substitute for form	1449B/I	то	Complete if Known		
	INFORMATION D	ISCLOS	SURE	Application Number	09/715,764	
STATEMENT BY APPLICANT				Filing Date	11/15/2000	
Date Submitted: March 3, 2006				First Named Inventor	Heinz-Josef LENZ	
Date Submitted. March 5, 2000			2000	Group Art Unit	1634	
	(use as many sheets	s as nec	essary)	Examiner Name	Sitton, Jehanne Souaya	
Sheet	3	of	3	Attorney Docket Number	064189-0201 (2924)	

		NON PATENT LITERATURE DOCUMENTS	-					
Examiner Initials* Cite No.1								
		PARK et al. "Thymidylate synthase gene polymorphism predicts response to capecitabine in advance colorectal cancer" Int. J. Colorectal Dis., Jan. 2002, Vol. 17, No. 1, pages 46-49.						
	17	PULLARKAT, et al. "Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy" Pharmacogenomics J., 2001, Vol. 1, No. 1, pages 65-70.						
	18	SALONGA et al. "Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihycropyrimidien dehydrogenase, thymidylate synthase, and thymidine phosphorylase" Clin. Cancer Res., April 2000, Vol. 6, pages 1322-1327.						
	19	SHIROTA et al. "ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy" J. Clin. Oncol., Dec. 2001, Vol. 19, No. 23, pages 4298-4304.						
	20	ULRICH et al. "Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene" Cancer Epidem., Biomarkers and Prevention, American Assoc. Cancer Res., Dec. 2000, Vol. 9, No. 12, pages 1381-1385.						
-	21	VILLAFRANCA et al. "Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer" J. Clin. Oncol., March 2001, Vol. 19, No. 6, pages 1779-1786.						
•	22	EP 03772163.6 Search Report dated 10/24/2005						
	23	EP 03772163.6 Search Report dated 02/03/2006						

Examiner Signature	Jehanne Sith	Date Considered	10/6/06	
-----------------------	--------------	--------------------	---------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-